DexTech Medical announces upcoming multiple myeloma study

The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, 2022. The study will include 20 patients and be conducted at 4-5 hospitals in Sweden and other Nordic countries. Studyn is expected to start in Q1 2023 and be completed during Q4, 2024.  Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The study duration for each individual patient is 14 weeks, from screening to follow-up visits. Each patient will receive OsteoDex every two weeks, a maximum of 7 doses. Adult MM patients with recurrent/treatment-resistant disease, who received 1-3 previous lines of therapy, will be included. The primary objective is to confirm safety and tolerability. The secondary objective is to determine treatmentresponse, change in the level of disease-related biomarkers, and documentation of quality of life (QoL scores).

For more information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-post: [email protected]

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 27, 2022.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the result shows high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after completing the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.